Baird Capital Portfolio Company Insightra Medical Announces FDA Clearance of the Freedom Octomesh Ventral Hernia System

Baird Capital's Venture Capital portfolio company Insightra Medical announced that the FDA has cleared Octomesh, its ventral hernia system, for use in the United States. Octomesh negates the need for slow, time-consuming suture fixation of sublay and pre-peritoneal hernia implants used in the treatment of ventral hernia.

Read Insightra's news release.